National Cancer InstituteU.S. National Institutes of Health | www.cancer.gov
U.S. National Institutes of Health www.cancer.gov

Home | About ICSN | Collaborative Projects | Meetings | Cancer Sites | Publications | Contact Us
Cervical Cancer: Mortality Rates | Organization of Screening Programs | Other Characteristics | HPV Vaccine Use

Cervical Cancer Screening Programs in 19 ICSN Countries, 2012: HPV Vaccine Use and Other HPV Vaccine Characteristics*

Region/Country Is the HPV Vaccine approved for use? Does program collect information on vaccination status? Components Collected Is there a vaccine registry in the country?
Australia Yes No Yes
Canada Yes Yes, but only in some provinces HPV vaccine type (quadrivalent or bivalent) Number of doses
Age at vaccination
Age at each dose
Yes, in some provinces
China under review
Denmark Yes No Yes
Finland Yes No No
France Yes No No
Georgia Yes Yes, verified medical record data HPV vaccine type (quadrivalent or bivalent) Number of doses
Age at vaccination 
Age at each dose
No
Iceland Yes No Yes
Italy Yes No Yes
Japan Yes No No
Korea Yes No No
Netherlands Yes Not sure/don't know Yes
New Zealand Yes No Yes
Norway Yes No Yes
Poland under review No No
Portugal (Alentejo Region) Yes Not sure/don't know Yes
Portugal (Central Region) Yes No No
United Kingdom Yes Yes, verified medical record data HPV vaccine type (quadrivalent or bivalent) Number of doses
Age at each dose
No
United States Yes No Yes, in some regions

*Data are from a survey of ICSN country representatives, conducted in 2012